Meningioma grading: An analysis of histologic parameters

American Journal of Surgical Pathology

Volumn 21, Issue 12, 1997, Pages 1455-1465

  Perry, Arie ^a   Stafford, Scott L ^a   Scheithauer, Bernd W ^a   Suman, Vera J ^b   Lohse, Christine M ^b  

^a MAYO CLINIC   (United States)

^b Department of Biostatistics ^*  (United States)

Author keywords

Anaplasia; Meningioma; Mitotic index; Necrosis; Neoplasm invasiveness; Prognosis; Recurrence

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; PROGNOSIS; SEX DIFFERENCE; SURVIVAL RATE; TUMOR VOLUME;

ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; CELL NUCLEOLUS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MITOSIS; NECROSIS; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 0030687656     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199712000-00008     Document Type: Article

References (62)

1. Böker D-K, Meurer H, Gullotta F. Recurring intracranial meningiomas. Evaluation of some factors predisposing for tumor recurrence. J Neurosurg Sci 1985;29:11-7.
2. Bouillot P, Pellissier J-F, Devictor B, et al. Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas. J Neurosurg 1994;81:765-73.
3. Chen WYK, Liu HC. Atypical (anaplastic) meningioma: relationship between histologic features and recurrence - a clinicopathologic study. Clin Neuropathol 1990;9:74-81.
4. Christensen D, Laursen H, Klinken L. Prediction of recurrence in meningiomas after surgical treatment. A quantitative approach. Acta Neuropathol 1983;61:130-4.
5. Condra KS, Buatti JM, Friedman WA, Mendenhall WM, Marcus RB. Treatment of benign meningioma: the role of radiotherapy. Int J Radiat Oncol Biol Phys 1995;32:276.
6. Crone KR, Challa VR, Kute TE, Moody DM, Kelly DL Jr. Relationship between flow cytometric features and clinical behavior of meningiomas. Neurosurgery 1988;23:720-4.
7. Cruz-Sánchez FF, Miquel R, Rossi ML, Figols J, Palacin A, Cardesa A. Clinico-pathological correlations in meningiomas: a DNA and immunohistochemical study. Histol Histopathol 1993;8:1-8.
8. de la Monte SM, Flickinger J, Linggood RM. Histopathologic features predicting recurrence of meningiomas following subtotal resection. Am J Surg Pathol 1986;10:836-43.
9. DeMonte F. Current management of meningiomas. Oncology 1995;9:83-91.
10. Deprez RHL, Riegman PH, van Drunen E, et al. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol 1995;54:224-35.
11. Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. J Neurosurg 1994;80:195-201.
12. Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 1993;15:75-7.
13. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74:861-6.
14. Haie-Meder C, Brunel P, Cioloca C, et al. Role of radiotherapy in the treatment of meningioma (French). Bulletin du cancer. Radiotherapie 1995;82:35-9.
15. Hsu DW, Pardo FS, Efird JT, Linggood RM, Hedley-Whyte ET. Prognostic significance of proliferative indices in meningiomas. J Neuropathol Exp Neurol 1994;53:247-55.
16. Ironside JW, Battersby RDE, Lawry J, Loomes RS, Day CA, Timperley WR. DNA in meningioma tissues and explant cell cultures. A flow cytometric study with clinicopathological correlates. J Neurosurg 1987;66:588-94.
17. Jääskeläinen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 1986;25:233-42.
18. Jääskeläinen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 1986;26:461-9.
19. Jellinger K, Slowik F. Histological subtypes and prognostic problems in meningiomas. J Neurol 1975;208:279-98.
20. Kallio M, Sankila R, Hakulinen T, Jääskeläinen J. Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 1992;31:2-12.
21. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:47-54.
22. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System. World Health Organization. Berlin: Springer-Verlag. 1993.
23. Kondziolka D, Lunsford LD, Coffey RJ, Flickinger JC. Stereotactic radiosurgery of meningiomas. J Neurosurg 1991;74:552-9.
24. Kumar PP, Patil AA, Leibrock LG, Chu WK, Syh J, McCaul GF, Reeves MA. Brachytherapy: a viable alternative in the management of basal meningiomas. Neurosurgery 1991;29:676-80.
25. Lamberts SW, Tanghe HL, Avezaat CJ, et al. Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 1992;55:486-90.
26. Langford LA, Cooksley CS, DeMonte F. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Hum Pathol 1996;27:350-4.
27. Lee KS, Hoshino T, Rodriguez LA, Bederson J, Davis RL, Wilson CB. Bromodeoxyuridine labeling study of intracranial meningiomas: proliferative potential and recurrence. Acta Neuropathol 1990;80:311-7.
28. Lesch KP, Gross S. Estrogen receptor immunoreactivity in meningiomas. Comparison with the binding activity of estrogen, progesterone, and androgen receptors. J Neurosurg 1987;67:237-43.
29. López-Ginés C, Cerdá-Nicolás M, Barcia-Salorio JL, Llombart-Bosch A. Cytogenetical findings of recurrent meningiomas. A study of 10 tumors. Cancer Genet Cytogenet 1995;85:113-7.
30. Lunsford LD. Contemporary management of meningiomas: radiation therapy as an adjuvant and radiosurgery as an alternative to surgical removal? J Neurosurg 1994;80:187-90.
31. MacCarty CS, Taylor WF. Intracranial meningiomas: experiences at the Mayo Clinic. Neurologia Medico-Chirurgica 1979;19:569-74.
32. Mahmood A, Caccamo DV, Tomecek FJ, Malik GM. Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery 1993;33:955-63.
33. Mahmood A, Qureshi NH, Malik GM. Intracranial meningiomas: analysis of recurrence after surgical treatment. Acta Neurochir 1994;126:53-8.
34. Maier H, Öfner D, Hittmair A, Kitz K, Budka H. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 1992;77:616-23.
35. May PL, Broome JC, Lawry J, Buxton RA, Battersby RDE. The prediction of recurrence in meningiomas. A flow cytometric study of paraffin-embedded archival material. J Neurosurg 1989;71: 347-51.
36. McLean CA, Jolley D, Cukier E, Giles G, Gonzales MF. Atypical and malignant meningiomus: importance of micronecrosis as a prognostic indicator. Histopathology 1993;23:349-53.
37. Miller DC. Predicting recurrence of intracranial meningiomas. A multivariate clinicopathologic model - interim report of the New York University Medical Center Meningioma Project. Neurosurg Clin North Am 1994;5:193-200.
38. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985;62:18-24.
39. Nagashima G, Aoyagi M, Wakimoto H, Tamaki M, Ohno K, Hirakawa K. Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Neurosurgery 1995;37:478-83.
40. Nakasu S, Nakajima M, Matsumura K-i, Nakasu Y, Handa J. Meningioma: proliferating potential and clinicoradiological features. Neurosurgery 1995;37:1049-55.
41. New PF, Hesselink JR, O'Carroll CP, Kleinman GM. Malignant meningiomas: CT and histologic criteria, including a new CT sign. Am J Neuroradiol 1982;3:267-76.
42. Ohta M, Iwaki T, Kitamoto T, Takeshita I, Tateishi J, Fukui M. MIB1 staining index and scoring of histologic features in meningioma. Cancer 1994;74:3176-89.
43. Paulus W, Meixensberger J, Hofmann E, Roggendorf W. Effect of embolization of meningioma on Ki-67 proliferation index. J Clin Pathol 1993;46:876-7.
44. Perrot-Applanat M, Groyer-Picard MT, Kujas M. Immunocytochemical study of progesterone receptor in human meningioma. Acta Neurochir 1992;115:20-30.
45. Perry A, Jenkins RB, Dahl RJ, Moertel CA, Scheithauer BW. Cytogenetic analysis of aggressive meningiomas. Possible diagnostic and prognostic implications. Cancer 1996;77:2567-73.
46. Rohringer M, Sutherland GR, Louw DF, Sima AAF. Incidence and clinicopathological features of meningioma. J Neurosurg 1989;71: 665-72.
47. Rose GE. Orbital meningiomas: surgery, radiotherapy, or hormones? Br J Ophthalmol 1993;77:313-4.
48. Sankila R, Kallio M, Jääskeläinen J, Hakulinen T. Long-term survival of 1986 patients with intracranial meningioma diagnosed from 1953 to 1984 in Finland. Cancer 1992;70:1568-76.
49. Scarpelli M, Montironi R, Sisti S, Mariuzzi GM. Quantitative evaluation of recurrent meningiomas. Pathol Res Pract 1989;185: 746-51.
50. Schneider BF, Shashi V, von Kap-herr C, Golden WL. Loss of chromosomes 22 and 14 in the malignant progression of meningiomas. Cancer Genet Cytogenet 1995;85:101-4.
51. Servo A, Porras M, Jääskeläinen J, Paetau A, Haltia M. Computed tomography and angiography do not reliably discriminate malignant meningiomas from benign ones. Neuroradiology 1990;32: 94-7.
52. Shibuya M, Hoshino T, Ito S, Wacker MR, Prados MD, Davis RL, Wilson CB. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling. Neurosurgery 1992;30:494-7.
53. Simon M, von Deimling A, Larson JJ, et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 1995;55:4696-701.
54. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20:22-39.
55. Skullerud K, Löken AC. The prognosis in meningiomas. Acta Neuropathol 1974;29:337-44.
56. Stafford SL, Perry A, Suman V, et al. Outcome and analysis of prognostic factors of primarily resected tumors. Int J Radiat Oncol Biol Phys 1996;36(suppl):287.
57. Strachan R, Clarke C, Nurbhai M, Marks S. Will chromosome karyotyping of meningiomas aid prediction of tumour recurrence? Br J Neurosurg 1989;3:583-90.
58. Taylor BW, Marcus RB. The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1988;15:299-304.
59. Vagner-Capodano AM, Grisoli F, Gambarelli D, Sedan R, Pellet W, De Victor B. Correlation between cytogenetic and histopathological findings in 75 human meningiomas. Neurosurgery 1993;32:892-900.
60. Yamashita J, Handa H, Iwaki K, et al. Recurrence of intracranial meningiomas, with special reference to radiotherapy. Surg Neurol 1996;14:33-40.
61. Yao Y-T. Clinicopathologic analysis of 615 cases of meningioma with special reference to recurrence. J Formos Med Assoc 1994;93:145-52.
62. Zülch KJ. Histologic typing of tumors of the central nervous system. International Histological Classification of Tumours. No. 21. Geneva: World Health Organization, 1979.